NAUT
Nautilus Biotechnology, Inc.
Biotechnology · Healthcare · United States
2.73
close · 2026-10-30
value
28
cheaper than peers28
quality
24
stronger fundamentals24
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| price to book | 2.98× | 55 |
| earnings yield, 2 years ago | -18.7% | 48 |
| earnings yield, 3 years ago | -16.8% | 48 |
| earnings yield, 1 year ago | -20.5% | 44 |
| earnings yield, latest year | -17.2% | 43 |
| cash flow yield, latest year | -14.9% | 42 |
| cash flow yield, 3 years ago | -13.8% | 38 |
| cash flow yield, 1 year ago | -17.6% | 37 |
| cash flow yield, 2 years ago | -15.6% | 36 |
| price to sales | 1830.14× | 3 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| return on equity | -36.2% | 64 |
| debt to equity | 21.2% | 46 |
| operating margin | -8296.3% | 2 |
3 of 4 measures available
Facts
| market cap | $348M |
| free cash flow | -$29.4M |
| employees | 127 |
| first trade | 2020-08-07 |
| next earnings | 2026-10-27 |
| fundamentals updated | 2026-10-27 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.47 | -0.56 | -0.51 | -0.46 |
| free cash flow | -$52.0M | -$61.3M | -$54.2M | -$48.1M |
| net income | -$59.0M | -$70.8M | -$63.7M | -$57.9M |
| revenue | $0 | $0 | $0 | $0 |